The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
Open accessAbstract
Rasagiline [N‐propargyl‐1R(+)‐aminoindan], was examined for its monoamine oxidase (MAO) A and B inhibitor activities in rats together with its S(−)‐enantiomer (TVP 1022) and the racemic compound (AGN‐1135) and compared to selegiline (1‐deprenyl). The tissues that were studied for MAO inhibition were the brain, liver and small intestine. While rasagiline and AGN1135 are highly potent selective irreversible inhibitors of MAO in vitro and in vivo, the S(−) enantiomer is relatively inactive in the tissues examined. The in vitro IC 50 values for inhibition of rat brain MAO activity by rasagiline are 4.43±0.92 n M (type B), and 412±123 n M (type A). The ED 50 values for ex vivo inhibition of MAO in the brain and liver by a single dose of rasagiline are 0.1±0.01, 0.042±0.0045 mg kg−1 respectively for MAO‐B, and 6.48±0.81, 2.38±0.35 mg kg−1 respectively for MAO‐A. Selective MAO‐B inhibition in the liver and brain was maintained on chronic (21 days) oral dosage with ED 50 values of 0.014±0.002 and 0.013±0.001 mg kg−1 respectively. The degree of selectivity of rasagiline for inhibition of MAO‐B as opposed to MAO‐A was similar to that of selegiline. Rasagiline was three to 15 times more potent than selegiline for inhibition of MAO‐B in rat brain and liver in vivo on acute and chronic administration, but had similar potency in vitro. These data together with lack of tyramine sympathomimetic potentiation by rasagiline, at selective MAO‐B inhibitory dosage, indicate that this inhibitor like selegiline may be a useful agent in the treatment of Parkinson's disease in either symptomatic or L‐DOPA adjunct therapy, but lack of amphetamine‐like metabolites could present a therapeutic advantage for rasagiline. British Journal of Pharmacology (2001) 132, 500–506; doi:10.1038/sj.bjp.0703826
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Bach, A. W., Lan, N. C., Johnson, D. L., Abell, C. W., Bembenek, M. E., Kwan, S. W., Seeburg, P. H., & Shih, J. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4934 · Cited by 723
Some puzzling pharmacological effects of monoamine oxidase inhibitors.
Knoll, J. E., & Magyar, K. (1972) · PubMed · Cited by 560
Birkmayer, W., Riederer, P., Youdim, M. B. H., & Linauer, W. (1975) · Journal of Neural Transmission · doi:10.1007/bf01253131 · Cited by 363
Self-citationSquires, R. F. (1972) · PubMed · Cited by 311
IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE
Birkmayer, W., Riederer, P., Ambrozi, L., & Youdim, M. B. H. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91940-7 · Cited by 297
Self-citationDEPRENYL IN PARKINSON'S DISEASE
Lees, A. J., Kohout, L. J., Shaw, K. M., Stern, G. M., Elsworth, J. D., Sandler, M., & Youdim, M. B. H. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90725-5 · Cited by 292
Self-citation(1947) · The Lancet · doi:10.1016/s0140-6736(47)90440-6 · Cited by 261
O'Carroll, A.-M., Fowler, C. J., Phillips, J. P., Tobbia, I., & Tipton, K. F. (1983) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00500765 · Cited by 230
Kearney, E. B., Salach, J. I., Walker, W. H., Seng, R. L., Kenney, W., Zeszotek, E., & Singer, T. P. (1971) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1971.tb19689.x · Cited by 208
Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal
Fowler, J. S., Volkow, N. D., Logan, J., Wang, G., Gregor, R. R. M., Schlyer, D. J., Wolf, A. P., Pappas, N. R., Alexoff, D. L., Shea, C. E., et al. (1994) · Synapse · doi:10.1002/syn.890180203 · Cited by 147
GREEN, A. R., Mitchell, B., Tordoff, A. F. C., & Youdim, M. B. H. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07506.x · Cited by 146
Self-citationHuang, W., Chen, Y., Shohami, E., & Weinstock, M. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00929-7 · Cited by 141
SELECTIVE ACETYLENIC ‘SUICIDE’ AND REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPES A AND B
Kalir, A., Sabbagh, A., & Youdim, M. B. H. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb16771.x · Cited by 134
Self-citationReynolds, G. P., Riederer, P. F., Sandler, M., Jellinger, K. A., & Seemann, D. (1978) · Journal of Neural Transmission · doi:10.1007/bf01246964 · Cited by 125
Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor
Finberg, J. P. M., Takeshima, T., Johnston, J. M., et al. (1998) · Neuroreport · doi:10.1097/00001756-199803090-00026 · Cited by 106
Self-citationTYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B
Finberg, J. P. M., Tenne, M., & Youdim, M. B. H. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb16772.x · Cited by 103
Self-citationPharmacology and neuroprotective properties of rasagiline
Finberg, J. P. M., Lamensdorf, I., Commissiong, J. W., & Youdim, M. B. H. (1996) · Springer eBooks · doi:10.1007/978-3-7091-7494-4_9 · Cited by 83
Self-citationPharmacology of rasagiline (N-propargyl-1R-aminoindan).
Finberg, J. P. M., Lamensdorf, I., Weinstock, M., Schwartz, M., & Youdim, M. B. H. (1999) · PubMed · Cited by 79
Self-citationEffects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders
Speiser, Z., Levy, R., & Cohen, S. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6499-0_29 · Cited by 74
Finberg, J. P. M., & Youdim, M. B. H. (1985) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1985.tb08891.x · Cited by 45
Self-citationYoudim, M. B. H. (1978) · Journal of Neural Transmission · doi:10.1007/bf01246956 · Cited by 29
Self-citationMaître, L., Delini‐Stula, A., & Waldmeier, P. C. (1976) · Novartis Foundation symposium · doi:10.1002/9780470720219.ch13 · Cited by 19
Cited by
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
Youdim, M. B. H., & Bakhle, Y. S. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706464 · Cited by 643
Self-citationTreatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Metadata
- Authors
- Youdim, M. B. H., Gross, A., & Finberg, J. P. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 132
- Issue
- 2
- Pages
- 500-506
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2082953267
- Cited by
- 342
- References
- 24
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.